查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1973759

青光眼房水湿化引流装置市场：按装置类型、材质、最终用户和分销管道划分 - 全球预测 2026-2032

Glaucoma Aqueous Shunt Device Market by Device Type, Material, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，青光眼房水引流装置市场价值将达到 5.1984 亿美元，到 2026 年将成长至 5.5266 亿美元，到 2032 年将达到 7.6084 亿美元，复合年增长率为 5.59%。

主要市场统计数据
基准年 2025 5.1984亿美元
预计年份：2026年 5.5266亿美元
预测年份 2032 7.6084亿美元
复合年增长率 (%) 5.59%

本书全面概述了影响青光眼治疗中房水引流装置未来的临床、技术和商业性因素。

本导论部分为基于临床的青光眼治疗中房水引流装置的探索奠定了基础，重点在于技术差异及其对治疗路径的影响。在青光眼治疗领域，人们越来越需要能够平衡眼压控制、病人安全、手术适用性和长期生物相容性的装置。本报告整合了临床趋势、材料科学进展、分销动态和监管趋势，为装置製造商、临床医生和投资者提供了一个统一的观点。

重大变革重新定义了整个医疗保健领域房水分流技术的产品设计、监管策略和分销方式。

产业格局的变革正在重塑青光眼房水引流管製造商的设计、监管合规和市场准入策略。首先，临床上对微创和可重复治疗效果的需求促使製造商重新评估装置的几何形状和流量控制机制，从而推动材料工程领域的渐进式创新和突破。其次，手术能力和成本效益正成为医疗系统的首要考虑因素，因此，能够实现可预测的手术时间和高效的术后管理的装置变得尤为重要。

贸易政策的变化和关税压力迫使製造商重新设计其采购、库存和製造策略，以保护利润率和供应链的连续性。

近期关税措施和贸易政策转变的累积效应，正给眼科器械製造商的供应链带来切实的压力，尤其是那些依赖国际采购的特种聚合物和组件的企业。半成品关税导致成本上升，挤压了利润空间，促使企业重新谈判供应商合同，并加速重新评估製造地。为此，许多企业正在审查关键投入品的总到岸成本，并透过优先选择具备本地生产能力和多元化贸易路线的供应商来降低风险。

实际細項分析揭示了设备类型、最终用户环境、分销方式和材料选择如何影响采用趋势。

关键的细分洞察揭示了器械类型、终端用户环境、分销管道和材料选择如何影响临床应用路径和商业性重点。按类型划分，器械分为非瓣膜植入（包括Aadi植入、Baerveldt植入和Molteno植入等设计）和瓣膜解决方案（例如Ahmed瓣膜）。这些区分对于外科医师的偏好、术后管理通讯协定和长期表现预期至关重要。终端使用者细分涵盖门诊手术中心、医院和专科眼科诊所，每个机构的采购流程、病例组成和手术能力预期各不相同，这些因素都会影响产品规格和服务模式。

区域观点与营运实务：展示医疗保健系统、采购规范和供应链如何影响全球市场中的设备部署。

区域趋势，源自于医疗基础设施、报销标准和临床实践模式的差异，导致房水分流装置的营运现状和应用曲线各不相同。在美洲，成熟的医院系统和专科诊所优先考虑长期疗效和安全性的验证，而门诊手术中心则越来越多地采用能够缩短手术时间和减轻术后追踪负担的装置。这就催生了对既能体现手术效率又能展现临床疗效的解决方案的需求。在欧洲、中东和非洲，由于监管协调、国家采购架构以及专科医疗服务取得的差异，分流装置的应用情况更加多样化。因此，需要製定针对特定区域的监管策略和定价方法。

企业对竞争考察和策略的洞察：揭示创新、伙伴关係和临床证据如何推动差异化和市场进入成功。

主要企业之间的竞争格局呈现出两极化：既有拥有成熟临床经验的老牌企业，也有专注于材料创新和低成本製造的参与企业。成熟的外科植入製造商通常依靠临床医生的认可、全面的培训计画以及提供短期临床支援的分销网络来竞争。而新参与企业则力求透过创新的材料方法、模组化或微创设计以及针对门诊手术中心和诊所的定向商业性提案来取代现有产品，并展现出卓越的运营能力。

为确保可持续的竞争优势，提出整合临床证据、健全的采购和客製化商业策略的实用建议。

产业领导者应采取平衡策略，将目标明确的临床证据的获取与切实可行的供应链优化和客製化的商业化模式相结合。优先进行针对医院和门诊手术中心关键运作终点（例如手术时间、併发症发生率和术后资源利用率）的临床研究，同时也要关注影响临床医师决策的以病人为中心的结局指标。此外，还应投资于供应商多元化，并对替代聚合物来源进行认证，以降低关税风险和对单一供应商的依赖风险。

采用稳健的混合调查方法，结合专家访谈、临床文献回顾和供应链分析，确保获得基于证据的见解。

本调查方法采用混合方法，结合了对外科医生、采购负责人和行业高管的定性访谈，以及对同行评审的临床文献、监管申报文件和供应商文件的详细审查。主要访谈着重于医疗设备在真实临床环境中的表现、不同医疗环境下的应用驱动因素以及采购决策标准。次要研究则整合了临床结果数据、医疗设备标籤资讯和监管摘要，以及与分流器製造中常用聚合物相关的材料科学文献。

为了推动产品普及，需要进行果断的整合，强调以证据为基础的产品策略、供应链弹性、以及通路特定的商业化。

总之，脑积水引流装置市场正处于转折点，其驱动因素包括不断变化的临床预期、材料技术的创新以及影响采购和分销的地缘政治压力。成功需要多管齐下的策略，该策略需协调设备设计选择与终端用户的操作需求，预见监管和关税方面的挑战，并制定针对医院、门诊手术中心和专科诊所具体特点的分销方案。那些采取实证方法、投资于供应链韧性并制定符合各医疗机构实际情况的商业化策略的公司，将更有利于最大限度地提升临床和商业性价值。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 青光眼房水引流装置市场：依装置类型划分

  • 无阀型
    • Ardi植入
    • 裸带植入
    • 莫尔特诺植入
  • 带阀门

第九章 青光眼房水引流装置市场：依材料分类

  • 聚二甲基硅氧烷
  • 聚丙烯
  • 硅酮

第十章 青光眼房水引流装置市场：依最终用户划分

  • 门诊手术中心
  • 医院
  • 眼科诊所

第十一章 青光眼房水引流装置市场：依通路划分

  • 直销
  • 第三方经销商

第十二章 青光眼房水引流装置市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 青光眼房水引流装置市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 青光眼房水引流装置市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国青光眼房水引流装置市场

第十六章：中国青光眼房水湿化引流装置市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alcon Inc.
  • Bausch+Lomb Corporation
  • Carl Zeiss Meditec AG
  • Glaukos Corporation
  • iSTAR Medical SA
  • Ivantis, Inc.
  • Johnson & Johnson Vision Care, Inc.
  • MicroSurgical Technology, Inc.
  • New World Medical, Inc.
  • Nova Eye Medical Limited
  • Ocular Therapeutix, Inc.
  • OPTI Medical Systems, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • STAAR Surgical Company
Product Code: MRR-546E6FBB35F9

The Glaucoma Aqueous Shunt Device Market was valued at USD 519.84 million in 2025 and is projected to grow to USD 552.66 million in 2026, with a CAGR of 5.59%, reaching USD 760.84 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 519.84 million
Estimated Year [2026] USD 552.66 million
Forecast Year [2032] USD 760.84 million
CAGR (%) 5.59%

A comprehensive introduction framing clinical, technological, and commercial considerations shaping the future of aqueous shunt devices in glaucoma care

The introduction sets the stage for a focused, clinically grounded exploration of aqueous shunt devices used in glaucoma care, emphasizing technological differentiation and care pathway impact. Glaucoma management increasingly requires devices that balance intraocular pressure control with patient safety, surgical adaptability, and long-term biocompatibility. This report synthesizes clinical trends, material science advances, distribution dynamics, and regulatory developments to provide a coherent perspective for device manufacturers, clinicians, and investors.

Recent years have seen intensified scrutiny of device performance across diverse clinical settings, ranging from tertiary hospitals to high-volume ambulatory surgical centers and specialized ophthalmic clinics. As such, the conversation around aqueous shunts is shifting from purely technical efficacy to a broader evaluation that includes operational efficiency, cost of care, and the ability to integrate into evolving glaucoma treatment algorithms. This introduction frames the subsequent sections by highlighting how device type, end user environment, distribution choices, and material composition collectively influence adoption pathways and commercial strategies.

Key transformative shifts redefining product design, regulatory strategy, and distribution approaches for aqueous shunt technologies across care settings

Transformative shifts in the landscape are reshaping how manufacturers approach design, regulatory engagement, and market entry for glaucoma aqueous shunts. First, the clinical imperative for minimally invasive and reproducible outcomes is driving a reevaluation of device geometry and flow control mechanisms, encouraging incremental innovation as well as step-changes in materials engineering. Second, health systems are prioritizing surgical throughput and cost efficiency, which elevates the importance of devices that facilitate predictable operative times and streamlined postoperative management.

At the same time, regulatory frameworks have become more stringent around long-term safety data and post-market surveillance, prompting developers to invest earlier in real-world evidence generation and structured registries. Distribution models are also evolving, with manufacturers exploring direct-sales relationships for complex hospital accounts while leveraging third-party distributors to expand reach into ambulatory surgical centers and specialty clinics. Finally, supply-chain resilience and supplier qualification have gained strategic importance, encouraging a dual focus on supplier diversification and tighter quality controls to mitigate disruptions and ensure consistent material performance.

How trade policy shifts and tariff pressures compel manufacturers to redesign sourcing, inventory, and manufacturing strategies to protect margins and supply continuity

The cumulative impact of recent tariff actions and trade policy shifts has created tangible pressure points across the supply chain for ophthalmic device manufacturers, particularly those reliant on specialized polymers and components sourced internationally. Tariff-driven cost increases on intermediate goods can compress margins, prompt renegotiation of supplier contracts, and accelerate reconsideration of manufacturing footprints. In response, many organizations are reassessing the total landed cost of key inputs, prioritizing suppliers with local manufacturing capabilities or diversified trade corridors to reduce exposure.

Moreover, tariff volatility influences inventory policies and capital allocation; companies may increase buffer inventories for critical components or invest in dual-sourcing strategies to maintain continuity of supply. These operational choices have knock-on effects for cash flow and working capital, reinforcing the need for integrated procurement and finance planning. Regulatory compliance and customs practices also require greater attention, as misclassification or inadequate documentation can exacerbate tariff burdens. Ultimately, the policy landscape is shifting competitive dynamics by advantaging firms that proactively adapt sourcing strategies, enhance supplier relationships, and invest in manufacturing flexibility within lower-risk jurisdictions.

Actionable segmentation intelligence revealing how device type, end-user environments, distribution approaches, and material choices drive adoption dynamics

Key segmentation insights illuminate how device type, end-user environment, distribution channel, and material selection each shape clinical adoption pathways and commercial priorities. Devices categorized by type split into non-valved implants, which include designs such as Aadi implant, Baerveldt implant, and Molteno implant, and valved solutions represented by options like the Ahmed valve; these distinctions matter for surgeon preference, postoperative management protocols, and long-term performance expectations. End-user segmentation spans ambulatory surgical centers, hospitals, and specialized ophthalmic clinics, each presenting distinct procurement processes, case-mix considerations, and procedural throughput expectations that influence product specification and service models.

Distribution dynamics are also consequential: manufacturers leveraging direct-sales models often secure deep clinical engagement and provide tailored training for hospital accounts, whereas third-party distributors can extend reach into distributed ambulatory centers and independent clinics but may require streamlined product portfolios and robust collateral. Material segmentation that differentiates polydimethylsiloxane, polypropylene, and silicone underlines how biocompatibility, flexibility, and manufacturing scalability affect both device performance and regulatory pathways. When these segmentation dimensions are considered together, they reveal actionable vectors for targeted clinical studies, value proposition refinement, and channel-specific commercialization tactics.

Regional perspectives and operational realities showing how healthcare systems, procurement norms, and supply chains shape device adoption across global markets

Regional dynamics create different operational realities and adoption curves for aqueous shunt devices, driven by healthcare infrastructure, reimbursement norms, and clinical practice patterns. In the Americas, established hospital systems and specialty clinics prioritize evidence of long-term efficacy and safety, while ambulatory surgical centers increasingly adopt devices that reduce operative time and postoperative follow-up burden; this creates demand for solutions that can demonstrate procedural efficiency alongside clinical outcomes. Europe, the Middle East, and Africa present a varied landscape where regulatory harmonization, national procurement frameworks, and differing levels of access to subspecialty care produce a mosaic of adoption scenarios, requiring regionally tailored regulatory strategies and pricing approaches.

Asia-Pacific markets exhibit rapid uptake in centers of excellence and urban tertiary institutions, accompanied by growing domestic manufacturing capabilities and intense competition on price and service. Across all regions, alignment with local clinical opinion leaders and targeted real-world evidence programs enhances credibility and uptake. Furthermore, regional supply-chain considerations, such as proximity to polymer suppliers and cost implications of import tariffs, will influence choices around local manufacturing, assembly, and inventory deployment to support reliable distribution and timely clinical support.

Competitive and strategic company insights highlighting how innovation, partnerships, and clinical evidence drive differentiation and market entry success

Competitive dynamics among leading companies reflect a mix of legacy players with established clinical footprints and emerging entrants focused on materials innovation or cost-effective manufacturing. Established surgical implant manufacturers often compete on clinician familiarity, comprehensive training programs, and distributor networks that provide near-term clinical support. Newer entrants differentiate through novel material approaches, modular or minimally invasive designs, and targeted commercial propositions for ambulatory surgical centers and outpatient clinics, seeking to displace legacy devices by demonstrating operational advantages.

Strategic partnerships and acquisitions remain a prominent route to accelerate capability development, whether that involves integrating advanced polymer science, securing manufacturing scale, or enhancing geographic reach via established distributor relationships. Intellectual property around device geometry, flow-control mechanisms, and proprietary surface treatments is a focal point for competitive positioning. Companies that invest in robust post-market surveillance and high-quality clinical studies strengthen their value proposition with payers and procurement committees, while those that streamline logistics and reduce total cost of care appeal to high-throughput surgical environments.

Practical recommendations for leaders to combine clinical evidence, resilient sourcing, and tailored commercial approaches to secure durable competitive advantage

Industry leaders should pursue a balanced strategy that combines targeted clinical evidence generation with pragmatic supply-chain optimization and tailored commercialization models. Prioritize clinical studies that address operational endpoints important to hospitals and ambulatory surgical centers, such as procedural time, complication rates, and postoperative resource utilization, while also capturing patient-centered outcomes that influence clinician choice. Concurrently, invest in supplier diversification and qualify alternative polymer sources to mitigate tariff exposure and reduce single-supplier risk.

Commercially, align distribution strategies with end-user needs: deploy direct-sales resources for complex hospital accounts where clinical training and procedural support differentiate offerings, and engage third-party distributors to scale presence in ambulatory surgical centers and independent ophthalmic clinics. Emphasize durable materials and standardized manufacturing processes that facilitate regulatory approvals across regions and simplify inventory management. Finally, integrate pricing strategies with value-based narratives that communicate total cost-of-care benefits, and maintain agile cross-functional governance to respond rapidly to policy shifts and evolving clinical guidance.

Robust mixed-methods research methodology integrating expert interviews, clinical literature review, and supply-chain analysis to ensure evidence-based insights

The research methodology employed a mixed-methods approach combining primary qualitative interviews with surgeons, procurement officers, and industry executives, alongside a rigorous review of peer-reviewed clinical literature, regulatory filings, and supplier documentation. Primary interviews focused on real-world device performance, adoption drivers in distinct care settings, and procurement decision criteria. Secondary research synthesized clinical outcomes data, device labeling and regulatory summaries, and material science literature relevant to polymers commonly used in shunt construction.

Analytical frameworks included segmentation mapping across device type, end-user environment, distribution channel, and material selection to generate intersectional insights. Supply-chain analysis incorporated input from manufacturing and procurement specialists to evaluate sourcing risks, tariff exposure, and inventory strategies. Quality assurance of the research process relied on cross-validation between interview findings and published clinical evidence, and methodological limitations were addressed through sensitivity checks around expert interpretation and triangulation of diverse information sources.

A conclusive synthesis emphasizing the need for evidence-driven product strategies, supply resilience, and channel-tailored commercialization to drive adoption

In conclusion, the aqueous shunt landscape is at an inflection point defined by evolving clinical expectations, materials innovation, and geopolitical pressures that affect sourcing and distribution. Success requires a multidimensional strategy that harmonizes device design choices with end-user operational needs, anticipates regulatory and tariff-related challenges, and matches distribution approaches to the dynamics of hospitals, ambulatory surgical centers, and specialty clinics. Companies that adopt an evidence-first approach, invest in supply-chain resilience, and tailor commercialization to the realities of each care setting will be best positioned to capture clinical and commercial value.

Moving from insight to execution involves concrete decisions around clinical program prioritization, supplier qualification, and channel investments. Organizations that act decisively to align R&D roadmaps with demonstrable operational benefits, while preserving flexibility in manufacturing and sourcing, will accelerate adoption and reduce exposure to external shocks. The overarching imperative is to convert the aggregated insights presented here into focused initiatives that enhance patient outcomes and strengthen sustainable commercial performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Glaucoma Aqueous Shunt Device Market, by Device Type

  • 8.1. Non Valved
    • 8.1.1. Aadi Implant
    • 8.1.2. Baerveldt Implant
    • 8.1.3. Molteno Implant
  • 8.2. Valved

9. Glaucoma Aqueous Shunt Device Market, by Material

  • 9.1. Polydimethylsiloxane
  • 9.2. Polypropylene
  • 9.3. Silicone

10. Glaucoma Aqueous Shunt Device Market, by End User

  • 10.1. Ambulatory Surgical Center
  • 10.2. Hospital
  • 10.3. Ophthalmic Clinic

11. Glaucoma Aqueous Shunt Device Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Third Party Distributor

12. Glaucoma Aqueous Shunt Device Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Glaucoma Aqueous Shunt Device Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Glaucoma Aqueous Shunt Device Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Glaucoma Aqueous Shunt Device Market

16. China Glaucoma Aqueous Shunt Device Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alcon Inc.
  • 17.6. Bausch + Lomb Corporation
  • 17.7. Carl Zeiss Meditec AG
  • 17.8. Glaukos Corporation
  • 17.9. iSTAR Medical SA
  • 17.10. Ivantis, Inc.
  • 17.11. Johnson & Johnson Vision Care, Inc.
  • 17.12. MicroSurgical Technology, Inc.
  • 17.13. New World Medical, Inc.
  • 17.14. Nova Eye Medical Limited
  • 17.15. Ocular Therapeutix, Inc.
  • 17.16. OPTI Medical Systems, Inc.
  • 17.17. Santen Pharmaceutical Co., Ltd.
  • 17.18. STAAR Surgical Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY AADI IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY AADI IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY AADI IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY BAERVELDT IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY BAERVELDT IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY BAERVELDT IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MOLTENO IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MOLTENO IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MOLTENO IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY VALVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY VALVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY VALVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY POLYDIMETHYLSILOXANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY POLYDIMETHYLSILOXANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY POLYDIMETHYLSILOXANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY POLYPROPYLENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY POLYPROPYLENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY POLYPROPYLENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY SILICONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY SILICONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY SILICONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY OPHTHALMIC CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY OPHTHALMIC CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY OPHTHALMIC CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY THIRD PARTY DISTRIBUTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY THIRD PARTY DISTRIBUTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY THIRD PARTY DISTRIBUTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. GCC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GCC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. GCC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 105. GCC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 106. GCC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GCC GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. G7 GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. G7 GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. G7 GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 123. G7 GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 124. G7 GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. G7 GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NATO GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NATO GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 129. NATO GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 130. NATO GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. NATO GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY NON VALVED, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA GLAUCOMA AQUEOUS SHUNT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)